Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.53 |
| ▸ | CPB1 | P15086 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27142958 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL29370715 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL27142277 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL29401164 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL29401850 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL31624479 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL8823890 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL178815 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL22804067 | 1.00 | FOLH1 (0.62) | FOLH1KMT2AHDAC1HDAC2SIRT2 | |
| SCHEMBL23574786 | 0.97 | FOLH1 (0.58) | FOLH1KMT2AHDAC1HDAC2SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | claimed |
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| WO-2020252713-A1 | MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江智达药业有限公司 | 2020-12-24 | — | — | WO | disclosed |
| EP-1858538-B1 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS LTD (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20170246326-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | ROCHESTER INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246326-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | ROCHESTER INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-9598463-B2 | Mucin hypersecretion inhibitors and methods of use | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150274778-A1 | MUCIN HYPERSECRETION INHIBITORS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. | 2015-10-01 | — | — | US | disclosed |
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | CHEESMAN EDWARD H (US) | 2003-08-07 | — | — | US | disclosed |
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-07-31 | — | — | US | disclosed |
| US-6569402-B1 | Targeting moiety that binds to receptor upregulated during angiogenesis, and a radioisotope or diagnostically imageable moiety; receptor integrin and compound is a benzodiazepine, benzodiazepinedione, or dibenzotrihydroannulene nonapeptide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-27 | — | — | US | disclosed |
| US-6558649-B1 | Benzodiazepine nonpeptide targeting moiety bound to chelating group; diagnosis and treatment of cancer; imaging tumors; monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-06 | — | — | US | disclosed |
| US-6548663-B1 | Imaging tumors and cancer with radioisotope benzodiazepine metal complex as contrast agent | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-04-15 | — | — | US | disclosed |
| US-20030055213-A1 | Endothelin-antagonizing peptide | TANAKA TAKEO (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1140864-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6194195-B1 | PURE CULTURE; FOR PRODUCTION OF HYPOTENSIVE AGENTS AND THERAPIES FOR ASTHMA, CEREBRAL APOPLEXY, ANGINA PECTORIS, ACUTE RENAL FAILURE, CARDIAC INFARCTION, AND CEREBRAL VASOSPASM | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| WO-2000035887-A2 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | DU PONT PHARM CO (US) | 2000-06-22 | — | — | WO | disclosed |
| EP-0438873-A1 | Inhibitor of ribonucleotide reductase of herpes viruses | MERCK & CO. INC. (US) | 1991-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030143235-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, ADGRE5 | FOLH1 627/4885KMT2A 4821/4885HDAC1 3629/4885 |
| US-20030149262-A1 | Benzodiazepine vitronectin receptor antagonist pharmaceuticals | ADGRF1, GPR174, NPSR1 | FOLH1 900/4885KMT2A 3255/4885HDAC1 2745/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | FOLH1 695/4885KMT2A 1835/4885HDAC1 2191/4885 |
| US-20170246326-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | SLC43A1, TAP1, TFIP11 | FOLH1 229/4885KMT2A 1561/4885HDAC1 4350/4885 |
| US-20030055213-A1 | Endothelin-antagonizing peptide | NPY1R, ECE1, EDNRB | FOLH1 1145/4885KMT2A 3649/4885HDAC1 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.